Information Provided By:
Fly News Breaks for November 5, 2019
Nov 5, 2019 | 20:47 EDT
Piper Jaffray analyst Edward Tenthoff lowered his price target on Xencor to $46 after its Q3 results and also to reflect his reduced estimated value for XmAb5871 and XmAb7195 programs. The analyst notes that the company does not plan to advance its obexelimab, or XmAb5871, program in either IgG4-Related Disease or lupus without a partner, adding that the same applies to XmAb7195 in asthma. The analyst still keeps his Overweight rating on the stock.